Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Ensysce Biosciences, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 11 | 17 | +6 |
| Shares | 179.2K | 351.7K | +172.5K (+96.3%) |
| Value | $398.8K | $833.7K | +$434.9K (+109.0%) |
New holders (8)
Institutions that held Ensysce Biosciences, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DRW Securities, LLC | 69,145 | $163.9K | 0.01% |
| Vanguard Group Inc | 36,708 | $87.0K | 0.00% |
| Renaissance Technologies LLC | 15,574 | $36.9K | 0.00% |
| Citadel Advisors LLC | 14,518 | $34.4K | 0.00% |
| Virtu Financial LLC | 14,222 | $34.0K | 0.00% |
| XTX Topco Ltd | 10,957 | $26.0K | 0.00% |
| Tru Independence Asset Management 2, LLC | 10,500 | $24.9K | 0.02% |
| Assetmark, Inc | 13 | $31 | 0.00% |
Sold out (2)
Institutions that held Ensysce Biosciences, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Morgan Stanley | 378 | $843 |
| Raymond James Financial Inc | 94 | $210 |